The Future of Peptide Therapies The future of peptide therapies looks incredibly promising
Superiority testing followed a hierarchical order, beginning with the highest Cagrilintide dose versus placebo, using a two-sided 5% significance threshold
Long-term administration of nicotinamide mononucleotide mitigates age-associated physiological decline in mice
New cells emerge more rapidly
BPC-157 (Body Protection Compound) , , ,
Nonetheless, scientific research suggests that their combined growth hormone secretagogue actions may be particularly effective at achieving the following health outcomes: Increasing growth hormone circulation Though not exactly common, growth hormone deficiency affects enough people (1 in every 10,000 adults) and causes serious enough problems (depression, insulin resistance, increased body fat) that it behooves us to have a reliable treatment for it.10 To that end, several studies have vouched for CJC-1295 and ipamorelin, at least as separate therapies